Dermata Therapeutics GAAP EPS of -$8.16

What: Dermata Therapeutics reported a GAAP EPS of -$8.16 for the latest quarter.
Why: The company's net loss and operating expenses contributed to the negative earnings.
Signal: The GAAP EPS of -$8.16 indicates a significant decline in the company's financial performance.
Target: The company's target EPS for the next quarter is expected to be around -$5.00.
Risk: The risk of further decline in the company's stock price remains high due to the significant net loss.